DICE · Dice Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 |
|---|---|---|
| Revenue | - | $863.0K |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| R&D | $62.56M | $19.58M |
| SG&A | $25.66M | $5.00M |
| Total Operating Expenses | $88.22M | $24.58M |
| D&A | $661.0K | $697.0K |
| Operating Income | ($88.22M) | ($23.72M) |
| Interest Expense | - | $13.0K |
| Income Tax | - | - |
| Net Income | ($83.89M) | ($23.74M) |
| EPS - Basic | ($3.95) | - |
| EPS - Diluted | ($3.95) | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 |
|---|---|---|
| Cash & Equivalents | $461.39M | $115.83M |
| Accounts Receivable | - | - |
| Inventory | - | - |
| Accounts Payable | $3.08M | $1.71M |
| Current Assets | $577.76M | $323.91M |
| Total Assets | $593.98M | $325.75M |
| Current Liabilities | $15.15M | $10.88M |
| Long-term Debt | - | $1.92M |
| Total Liabilities | $26.99M | $12.80M |
| Stockholders' Equity | $566.99M | ($29.62M) |
| Retained Earnings | ($187.59M) | ($103.71M) |
Cash Flow
| Line item | FY 2022 | FY 2021 |
|---|---|---|
| Operating Cash Flow | ($64.32M) | ($20.68M) |
| Investing Cash Flow | $87.49M | $18.00M |
| Financing Cash Flow | $322.25M | $53.90M |
| CapEx | $2.24M | $148.0K |
| Free Cash Flow | ($66.56M) | ($20.83M) |
Ratios
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Profitability | ||
| Gross margin | - | - |
| Operating margin | - | -2748.7% |
| EBITDA margin | - | -2667.9% |
| Net margin | - | -2750.8% |
| Free cash flow margin | - | -2413.3% |
| FCF / Net income | 0.79 | 0.88 |
| R&D / Revenue | - | 2268.8% |
| SG&A / Revenue | - | 579.8% |
| Effective tax rate | - | - |
| Return on assets | -14.1% | -7.3% |
| Return on equity | -14.8% | 80.1% |
| Return on invested capital | - | - |
| Liquidity | ||
| Current ratio | 38.14 | 29.77 |
| Quick ratio | 38.14 | 29.77 |
| Cash ratio | 30.46 | 10.64 |
| Leverage | ||
| Debt / Equity | - | -0.06 |
| Debt / Assets | - | 0.01 |
| Debt / EBITDA | - | - |
| Interest coverage | - | -1824.7x |
| Equity multiplier | 1.05 | -11.00 |
| Liabilities / Assets | 0.05 | 0.04 |
| Efficiency | ||
| Asset turnover | - | 0.00 |
| Inventory turnover | - | - |
| Days sales outstanding | - | - |
| Days inventory outstanding | - | - |
| Days payable outstanding | - | - |
| Cash conversion cycle | - | - |
| Valuation | ||
| P / E | - | - |
| P / B | - | - |
| P / S | - | - |
| EV / EBITDA | - | - |
| Growth | ||
| Revenue growth (YoY) | - | - |
| Revenue CAGR (3y) | - | - |
| Revenue CAGR (5y) | - | - |
| Gross profit growth (YoY) | - | - |
| Operating income growth (YoY) | -271.9% | - |
| Net income growth (YoY) | -253.4% | - |
| EPS growth (YoY) | - | - |
| EPS CAGR (3y) | - | - |
| EPS CAGR (5y) | - | - |
| FCF growth (YoY) | -219.6% | - |
| FCF CAGR (5y) | - | - |
| Book value growth (YoY) | - | - |
Stability scores
Piotroski F-score
FY 2022 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- -No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing DICE Therapeutics against the 5 most active filers in the same SIC group.